Neurologic manifestations of Behçet disease: rheumatology experience.
Neurologische Manifestationen des M. Behçet: rheumatologische Erfahrungen.
Cerebral venous sinus thrombosis
Headache
Neuro-Behçet
Neurologic deficit
Vasculitis
Journal
Zeitschrift fur Rheumatologie
ISSN: 1435-1250
Titre abrégé: Z Rheumatol
Pays: Germany
ID NLM: 0414162
Informations de publication
Date de publication:
17 Oct 2023
17 Oct 2023
Historique:
accepted:
07
09
2023
medline:
18
10
2023
pubmed:
18
10
2023
entrez:
17
10
2023
Statut:
aheadofprint
Résumé
Neurologic involvement in Behçet disease (BD) is a rare manifestation. Herein, we aimed to evaluate the clinical features and treatment choices of neuro-Behçet (NB) patients. There were records of 800 BD patients between 1998 and 2021. Fifty-five of the BD patients had NB and the files of these patients were retrospectively evaluated. Patients were grouped into three subgroups: 22 (40%) had non-parenchymal, 25 (45%) had parenchymal, and 8 (15%) had both parenchymal and non-parenchymal (mixed) involvement. Of the 55 patients, 32 were male. Twenty-six of the NB patients were diagnosed with BD simultaneously. The most common complaint was headache (n = 24, 44%). The most affected site was periventricular white matter (n = 21, 38%). All patients had received corticosteroids. Azathioprine (AZA; n = 39, 71%) was the most common immunosuppressive agent after corticosteroids, followed by cyclophosphamide (n = 16, 29%). Neurologic involvement is a rare complication of BD but is related to increased mortality and morbidity. Neurologic manifestations may be the initial symptom of BD, thus leading to diagnosis. Both neurology and rheumatology specialists should be aware of this rare condition. ZIEL: Eine neurologische Beteiligung im Rahmen eines M. Behçet stellt eine seltene Manifestation dar. In der vorliegenden Arbeit war es das Ziel, die klinischen Merkmale und die zur Wahl stehenden Therapien bei Patienten mit Neuro-Behçet (NB) zu erörtern. Zwischen 1998 und 2021wurden 800 Fälle mit M. Behçet dokumentiert. Von den Patienten mit M. Behçet wiesen 55 einen NB auf, und die Krankenakten dieser Patienten wurden retrospektiv untersucht. Dabei wurden die Patienten in 3 Subgruppen unterteilt: Bei 22 (40%) bestand eine nichtparenchymale, bei 25 (45%) eine parenchymale und bei 8 (15%) sowohl eine parenchymale als auch eine nichtparenchymale (gemischte) Beteiligung. Von den 55 Patienten waren 32 männlich. Bei 26 der NB-Patienten wurde gleichzeitig die Diagnose M. Behçet gestellt. Das häufigste Symptom waren Kopfschmerzen (n = 24; 44%). Die meistbetroffene Lokalisation stellte die periventrikuläre weiße Substanz dar (n = 21; 38%). Alle Patienten hatten Kortikosteroide erhalten. Azathioprin (AZA; n = 39; 71%) war das am häufigsten verabreichte immunsupprimierende Präparat nach den Kortikosteroiden, dann folgte Cyclophosphamid (n = 16; 29%). Eine neurologische Beteiligung ist eine seltene Komplikation des M. Behçet, allerdings geht sie mit erhöhter Mortalität und Morbidität einher. Sowohl Neurologen als auch Rheumatologen sollten sich dieser seltenen Symptomkonstellation bewusst sein.
Autres résumés
Type: Publisher
(ger)
ZIEL: Eine neurologische Beteiligung im Rahmen eines M. Behçet stellt eine seltene Manifestation dar. In der vorliegenden Arbeit war es das Ziel, die klinischen Merkmale und die zur Wahl stehenden Therapien bei Patienten mit Neuro-Behçet (NB) zu erörtern.
Identifiants
pubmed: 37848717
doi: 10.1007/s00393-023-01436-0
pii: 10.1007/s00393-023-01436-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Yazici H, Seyahi E, Hatemi G, Yazici Y (2018) Behçet syndrome: a contemporary view. Nat Rev Rheumatol 14(2):107–119
doi: 10.1038/nrrheum.2017.208
pubmed: 29296024
Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V et al (2003) The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine 82(1):60–76. https://doi.org/10.1097/00005792-200301000-00006
doi: 10.1097/00005792-200301000-00006
pubmed: 12544711
Borhani-Haghighi A, Kardeh B, Banerjee S, Yadollahikhales G, Safari A, Sahraian MA et al (2019) Neuro-Behcet’s disease: an update on diagnosis, differential diagnoses, and treatment. Mult Scler Relat Disord 39:101906. https://doi.org/10.1016/j.msard.2019.101906
doi: 10.1016/j.msard.2019.101906
pubmed: 31887565
Akman-Demir G, Serdaroglu P, Tasçi B (1999) Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain 122(Pt 11):2171–2182. https://doi.org/10.1093/brain/122.11.2171
doi: 10.1093/brain/122.11.2171
pubmed: 10545401
Siva A, Kantarci OH, Saip S, Altintas A, Hamuryudan V, Islak C et al (2001) Behçet’s disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 248(2):95–103. https://doi.org/10.1007/s004150170242
doi: 10.1007/s004150170242
pubmed: 11284141
Benamour S, Naji T, Alaoui FZ, El-Kabli H, El-Aidouni S (2006) Manifestations neurologiques de la maladie de Behçet [Neurological involvement in Behçet’s disease. 154 cases from a cohort of 925 patients and review of the literature]. Rev Neurol 162(11):1084–1090. https://doi.org/10.1016/s0035-3787(06)75121-9
doi: 10.1016/s0035-3787(06)75121-9.
pubmed: 17086145
Al-Araji A, Kidd DP (2009) Neuro-Behçet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol 8(2):192–204. https://doi.org/10.1016/S1474-4422(09)70015-8
doi: 10.1016/S1474-4422(09)70015-8
pubmed: 19161910
International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335(8697):1078–1080
Kalra S, Silman A, Akman-Demir G, Bohlega S, Borhani-Haghighi A, Constantinescu CS et al (2013) Diagnosis and management of Neuro-Behçet’s disease: international consensus recommendations. J Neurol 261(9):1662–1676. https://doi.org/10.1007/s00415-013-7209-3
doi: 10.1007/s00415-013-7209-3
pubmed: 24366648
pmcid: 4155170
Uygunoğlu U, Siva A (2018) Behçet’s syndrome and nervous system involvement. Curr Neurol Neurosci Rep 18(7):35. https://doi.org/10.1007/s11910-018-0843-5
doi: 10.1007/s11910-018-0843-5
pubmed: 29789966
Farah S, Al-Shubaili A, Montaser A, Hussein JM, Malaviya AN, Mukhtar M et al (1998) Behçet’s syndrome: a report of 41 patients with emphasis on neurological manifestations. J Neurol Neurosurg Psychiatry 64(3):382–384. https://doi.org/10.1136/jnnp.64.3.382
doi: 10.1136/jnnp.64.3.382
pubmed: 9527155
pmcid: 2169980
Tursen U, Gurler A, Boyvat A (2003) Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet’s disease. Int J Dermatol 42(5):346–351. https://doi.org/10.1046/j.1365-4362.2003.01741.x
doi: 10.1046/j.1365-4362.2003.01741.x
pubmed: 12755969
Kidd DP (2017) Neurological complications of Behçet’s syndrome. J Neurol 264(10):2178–2183. https://doi.org/10.1007/s00415-017-8436-9
doi: 10.1007/s00415-017-8436-9
pubmed: 28283819
Bolek EC, Sari A, Kilic L, Kalyoncu U, Kurne A, Oguz KK et al (2020) Clinical features and disease course of neurological involvement in Behcet’s disease: HUVAC experience. Mult Scler Relat Disord 38:101512. https://doi.org/10.1016/j.msard.2019.101512
doi: 10.1016/j.msard.2019.101512
pubmed: 31733425
Monaco LA, La Corte R, Caniatti L, Borrelli M, Trotta F (2006) Neurological involvement in North Italian patients with Behçet disease. Rheumatol Int 26(12):1113–1119. https://doi.org/10.1007/s00296-006-0149-9
doi: 10.1007/s00296-006-0149-9
pubmed: 16794844
Joseph FG, Scolding NJ (2007) Neuro-Behçet’s disease in Caucasians: a study of 22 patients. Eur J Neurol 14(2):174–180. https://doi.org/10.1111/j.1468-1331.2006.01613.x
doi: 10.1111/j.1468-1331.2006.01613.x
pubmed: 17250726
Al-Fahad SA, Al-Araji AH (1999) Neuro-Behcet’s disease in Iraq: a study of 40 patients. J Neurol Sci 170(2):105–111. https://doi.org/10.1016/s0022-510x(99)00165-3
doi: 10.1016/s0022-510x(99)00165-3.
pubmed: 10561525
Aguiar de Sousa D, Mestre T, Ferro JM (2011) Cerebral venous thrombosis in Behçet’s disease: a systematic review. J Neurol 258(5):719–727. https://doi.org/10.1007/s00415-010-5885-9
doi: 10.1007/s00415-010-5885-9
pubmed: 21210139
Aykutlu E, Baykan B, Akman-Demir G, Topcular B, Ertas M (2006) Headache in Behçet’sdisease. Cephalalgia 26(2):180–186. https://doi.org/10.1111/j.1468-2982.2005.01017.x
doi: 10.1111/j.1468-2982.2005.01017.x
pubmed: 16426273
Domingos J, Ferrão C, Ramalho J, Rodrigues T, Moreira B, Santos E et al (2015) Characteristics of neuro-Behçet’s disease in a case-series from a single centre in northern Portugal. Eur Neurol 73(5–6):321–328. https://doi.org/10.1159/000381210
doi: 10.1159/000381210
pubmed: 25997636
Houman MH, Bellakhal S, Salem BT, Hamzaoui A, Braham A, Lamloum M et al (2013) Characteristics of neurological manifestations of Behçet’s disease: a retrospective monocentric study in Tunisia. Clin Neurol Neurosurg 115(10):2015–2018. https://doi.org/10.1016/j.clineuro.2013.06.009
doi: 10.1016/j.clineuro.2013.06.009
pubmed: 23830180
Al-Araji A, Sharquie K, Al-Rawi Z (2003) Prevalence and patterns of neurological involvement in Behcet’s disease: a prospective study from Iraq. J Neurol Neurosurg Psychiatry 74(5):608–613. https://doi.org/10.1136/jnnp.74.5.608
doi: 10.1136/jnnp.74.5.608
pubmed: 12700303
pmcid: 1738436
Farahangiz S, Sarhadi S, Safari A, Borhani-Haghighi A (2012) Magnetic resonance imaging findings and outcome of neuro-Behçet’s disease: the predictive factors. Int J Rheum Dis 15(6):e142–e149. https://doi.org/10.1111/1756-185X.12013
doi: 10.1111/1756-185X.12013
pubmed: 23253242
Shi J, Huang X, Li G, Wang L, Liu J, Xu Y et al (2018) Cerebral venous sinus thrombosis in Behçet’s disease: a retrospective case-control study. Clin Rheumatol 37(1):51–57. https://doi.org/10.1007/s10067-017-3718-2
doi: 10.1007/s10067-017-3718-2
pubmed: 28612244
Lee YB, Lee JH, Lee SY, Lee JH, Yu DS, Han KD et al (2019) Association between smoking and Behçet’s disease: a nationwide population-based study in Korea. J Eur Acad Dermatol Venereol 33(11):2114–2122. https://doi.org/10.1111/jdv.15708
doi: 10.1111/jdv.15708
pubmed: 31121063
Mahdavi MA, Khabbazi A, Yaaghoobian B, Ghojazadeh M, Agamohammadi R, Kheyrollahiyan A et al (2019) Cigarette smoking and risk of Behcet’s disease: a propensity score matching analysis. Mod Rheumatol 29(4):633–639. https://doi.org/10.1080/14397595.2018.1493065
doi: 10.1080/14397595.2018.1493065
Hirohata S (2013) Recent aspects of Neuro-Behcet’s disease. Brain Nerve 65(11):1245–1253
pubmed: 24200602
Yazici H, Pazarli H, Barnes CG, Tüzün Y, Ozyazgan Y, Silman A et al (1990) A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med 322(5):281–285. https://doi.org/10.1056/NEJM199002013220501
doi: 10.1056/NEJM199002013220501
pubmed: 2404204
London F, Hohenbichler K, Duprez T, Sindic C, van Pesch V (2019) Which treatment strategies for polyrefractory Neuro-Behçet disease? Mult Scler Relat Disord 27:203–205. https://doi.org/10.1016/j.msard.2018.10.117
doi: 10.1016/j.msard.2018.10.117
pubmed: 30408759
Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F et al (2018) 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis 77(6):808–818. https://doi.org/10.1136/annrheumdis-2018-213225
doi: 10.1136/annrheumdis-2018-213225
pubmed: 29625968